MCRB Seres Therapeutics
- 0.769
- +0.037+5.03%
- 0.790
- +0.021+2.76%
Seres Therapeutics News
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity
Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics
Seres Therapeutics Reports Q3 2024 Results and Strategic Progress
Express News | Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target
TD Cowen Maintains Seres Therapeutics(MCRB.US) With Buy Rating
Seres Therapeutics (MCRB) Gets a Buy From TD Cowen
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript Summary
Seres Therapeutics | 10-Q: Q3 2024 Earnings Report
Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript
Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success
Seres Therapeutics | 8-K: SERES THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
Seres Therapeutics GAAP EPS of -$0.33 Misses by $0.25
Express News | Seres Therapeutics Inc: Co Expects to Fund Operations Into Q4 2025
Seres Therapeutics 3Q Net $88.8M >MCRB
Express News | Seres Therapeutics Q3 Operating Income USD -29.17 Million
Earnings Scheduled For November 13, 2024
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Analysis
Price Target
No Data
No Data